EVELINE BARBIERI to Tumor Suppressor Protein p53
This is a "connection" page, showing publications EVELINE BARBIERI has written about Tumor Suppressor Protein p53.
Connection Strength
1.070
-
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clin Cancer Res. 2017 Nov 01; 23(21):6629-6639.
Score: 0.401
-
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One. 2013; 8(11):e79843.
Score: 0.310
-
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.
Score: 0.131
-
Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res. 2014 Feb 01; 74(3):765-74.
Score: 0.078
-
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006 Sep; 5(9):2358-65.
Score: 0.047
-
The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12).
Score: 0.033
-
NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis. Cell Death Dis. 2015 Aug 06; 6:e1841.
Score: 0.022
-
G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013 Jul 01; 73(13):4134-46.
Score: 0.019
-
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis. 2011 Sep; 14(3):255-66.
Score: 0.016
-
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia. 2009 Aug; 11(8):753-62.
Score: 0.014